Affordable Access

Publisher Website

Felbamate in refractory partial epilepsy

Authors
Journal
Epilepsy Research
0920-1211
Publisher
Elsevier
Publication Date
Volume
34
Issue
1
Identifiers
DOI: 10.1016/s0920-1211(98)00098-9
Keywords
  • Refractory Epilepsy
  • Felbamate
  • Partial Epilepsy
  • Open-Label Study
  • Efficacy
Disciplines
  • Medicine

Abstract

Abstract This open-label study was performed to evaluate efficacy and safety of Felbamate (FBM) add-on therapy in drug-refractory partial epilepsy. We evaluated 36 patients (12 males) aged 11–68 years (mean 29.8) in which FBM was titrated gradually from 300 mg/day to a mean total maintenance daily dose of 1936 mg. Patients were monitored according to clinical practice and performed regularly laboratory tests. Mean follow-up of FBM therapy was 10 months (range 2–27). In this study, 5% of patients resulted to be seizure-free, 11% showed a seizure reduction more than 75%, 23% decreased their seizure frequency between 50% and 75% ( P=0.0001). The adverse events which were reported more frequently were: nausea, vomiting, anorexia and weight loss. Even if the patients sample is small FBM proves its efficacy in partial epilepsy, showing a relatively well tolerated profile.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments

More articles like this

Felbamate in refractory partial epilepsy.

on Epilepsy Research March 1999

Felbamate as an add-on therapy for refractory epil...

on The Cochrane database of syste... 2011

Felbamate as an add-on therapy for refractory epil...

on The Cochrane database of syste... 2014
More articles like this..